Recent preclinical [7,8,9,10,11,12,13] and clinical [14] studies report that EMPA improves DKD and another SGLT2 inhibitor, canagliflozin, has been found to reduce the numbers of T2D patients with nephropathy progressing to kidney failure or death [15]. This evidence concerns the gene SLC5A2 and kidney disorder.